Gujarat Themis Biosyn FY26 audited results filed, clean audit opinion
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 3.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Themis Biosyn filed audited FY26 results (year ended March 31, 2026). Auditor GMJ & Co gave an unqualified opinion with no qualifications or going concern issues. Revenue rose to INR 16,582.28 lakhs from INR 15,079.99 lakhs, about 10 percent growth. Total assets jumped to INR 50,342.66 lakhs from INR 30,131.25 lakhs as capital work-in-progress was capitalized into PPE. Borrowings rose sharply to INR 15,986 lakhs. Results pending shareholder approval at AGM.
Clean audit and 10 percent revenue growth are positives. Big jump in borrowings and depreciation signals heavy capex that may pressure margins.